FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							· / ·		iivooanone c	,										
Name and Address of Reporting Person* Ferrante Karen Jean					2. Issuer Name and Ticker or Trading Symbol Unum Therapeutics Inc. [UMRX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Ferrant	e Karen .	<u>iean</u>			Onum Therapeuties me. [Owkx]							X D	irecto	r		10% Ow	ner			
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							\dashv	Officer (give title Other (sp below) below)				pecify			
C/O UNI		10/01/2020																		
200 CAMBRIDGE PARK DRIVE, SUITE 3100					If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)													Lir	Line)						
CAMBR	IDGE M	IA	02140													•		•		
,———	III IV.		02170											Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		Tal	ble I - Non-	Deriva	tive	Securi	ties	Acc	quired, D	spose	d o	f, or Be	neficia	lly Ow	ned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,		Code (Instr. 5)			ed (A) or itr. 3, 4 an	4 and Securitie Benefici		es Form ally (D) of Following (I) (Ir		: Direct II r Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code V	Amo	unt	(A) or (D)	Price	Tra	nsact str. 3 a	tion(s)			msu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Perivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		Co	ansaction Derivative Securities			(A) ed tr.	6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)				of s ng e Security			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	de V	(A)		(D)	Date Exercisable	Expira Date	tion	Title	Amoun or Numbe of Shares	1		(Instr. 4)	on(s)			
Stock Option (Right to Buy)	\$2.26	10/01/2020		Α	\	8,87	8(1)		(2)	10/01/2	2030	Common Stock	8,878	\$1.3	518	8,878	3	D		

Explanation of Responses:

1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Remarks:

/s/ Amoli Pandya, as Attorney-10/02/2020 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} This option is fully vested at time of grant.